Name | Value |
---|---|
Revenues | 492.5M |
Cost of Revenue | 359.3M |
Gross Profit | 133.2M |
Operating Expense | 48.3M |
Operating I/L | 84.9M |
Other Income/Expense | -1.7M |
Interest Income | 0.1M |
Pretax | 83.2M |
Income Tax Expense | 12.7M |
Net Income/Loss | 70.5M |
Medpace Holdings, Inc. provides comprehensive clinical research-based drug and medical device development services globally. The company offers a range of services supporting the clinical development process from Phase I to Phase IV across various therapeutic areas. Its services include clinical development, project management, regulatory affairs, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. Additionally, it provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace generates revenue by offering these services to pharmaceutical, biotechnology, and medical device industries.